- The Washington Times - Monday, December 2, 2002

REYKJAVIK, Iceland Steindor Erlingsson feels like the least popular man in Iceland.
The science historian, 36, has published a book debunking the national notion that Icelanders' Viking genes hold the key to curing diseases, developing new drugs and making the country rich.
"My family and friends tell me this book might ruin my career possibilities in Iceland," said Mr. Erlingsson, running a hand across a stubbly beard. "In a small society like this, you can't hide anywhere."
Mr. Erlingsson's target is Decode Genetics, the biotechnology company set up in 1996 to scour the country's genes for keys to disease.
The company's charismatic founder, Kari Stefansson, said Icelanders' detailed family trees and common descent from ninth-century Norwegian settlers formed a rich scientific resource that could unlock the secrets of cancer, mental illness and other devastating diseases.
Because scientists study family histories to track the route of a disease-causing gene, the theory runs that in Iceland they would be able to work with a sort of extended family of the entire population 280,000 people.
"Our Genes," Mr. Erlingsson's just-released Icelandic-language book, accuses Decode of shaky science, bad ethics and overly cozy ties with Iceland's politicians. But Icelanders a small, close-knit population with a strong pride in their roots embraced the project from the start.
Eighty thousand people gave blood samples. Thousands bought shares of stock in the firm before it went public on the Nasdaq exchange two years ago. Icelandic banks sold shares on the "gray market" for more than $60 each.
"This gene frenzy was going on in Iceland," said Mr. Erlingsson. "Decode was in the news every day. People were taking out loans to buy these stocks."
Many now wish they hadn't. The heroic Decode project is looking increasingly fallible.
The company has yet to make a profit. On Nov. 15, it announced a third-quarter net loss of $85.7 million. It recently laid off 200 employees, almost a third of the total, at its Reykjavik genetics lab.
Nonetheless, the company has amassed a vast amount of information on Icelanders. It says it has mapped genes linked to 25 diseases and isolated genes associated with increased susceptibility to seven ailments, including strokes and schizophrenia.
Mr. Stefansson, a former Harvard neuroscience professor, says the company's approach has been a "smashing success." (Decode's Internet site can be viewed at www.decode.com.)
Announcing the latest financial results, Mr. Stefansson declared that Decode was "making the transition from a discovery-based company to a company based on product development from gene discovery to drug development."
The company says it will break even by the end of 2003, but its shares, which debuted on the Nasdaq in July 2000 at $18 each, are worth about $2.50 now, swamped in the stock market gloom that has hit the high-tech industry as a whole.
"When it was going on, if you went to a bank or a trading company, everybody said, 'Whatever you do, buy Decode,'" said Jon Eldjarn Bjarnason, 38, a fishing-boat engineer. "Everybody who could loan you money was encouraging you to buy Decode. A lot of people put everything into it. Now they have no money nothing."
Mr. Bjarnason was lucky. With debts mounting from other investments, he sold his Decode shares at $48 just before the company went public. A lot of people he knew did not. They now are too embarrassed to speak to the press.
"I sold early. I was broke. I was lucky," he said.
"My mother had a 2 million krona [$20,000] loan and bought shares at $24. When they were at $64, she asked the bank if she should sell; they said no, it's going to be $100. Now she's stuck with them at $2 a share, and the bank says it wants the loan back."
Meanwhile, Mr. Bjarnason's other high-tech investments have tanked, driving him to the edge of bankruptcy.
Decode, in contrast, appears to have flourished.
Founded in 1996 with 20 employees and $12 million from venture capitalists, the company now employs about 450 people and has a shiny new wood-and-glass headquarters in Reykjavik.
In 1998, Decode signed a deal worth up to $200 million with Swiss pharmaceuticals giant Roche to look for genes that cause 12 common diseases. In September, it linked with U.S. pharmaceutical company Merck to develop anti-obesity drugs.
In May, Iceland's parliament, the Althingi, agreed to guarantee a $200 million bond issue as Decode sought more investment to develop new drugs.
The company says a breakthrough is only a matter of time. Meanwhile, the economic fallout has heightened criticism of Decode's close relationship with Iceland's government.
"The difference between Decode and other genomics companies is that they are located in one of the smallest economies in the world, and the government has done everything to help them," said Mr. Erlingsson, the "Our Genes" author.
Prime Minister David Oddsson appeared frequently with Mr. Stefansson in the company's early days. In 1998, parliament passed a law allowing a private company Decode, though no specific company was named to obtain medical records from everyone in the country.
Consent was assumed unless people opted out. Many doctors and medical ethicists were alarmed.
"Patients ask me: 'What will happen to my data? Will it end up in the hands of Decode? What will happen to my blood? Will it be used against me?'" said Petur Hauksson, a physician who heads the Association of Icelanders for Ethics in Science and Medicine, a group of anti-Decode scientists (on the Web at www.mannvernd.is.).
"Having these valuable records in the hands of a private company is worrying."
Others criticize the company's scientific approach, which uses "population genomics" to study the genetic causes of disease.
The company says Iceland's advantage is its detailed medical and genealogical records, and the relative homogeneity of its small population. It is estimated that fewer than 1 million people have inhabited Iceland since Norse settlers first arrived on the North Atlantic island.
Decode was inaugurated with plans to build linked databases of medical records, family trees and DNA samples to create a genetic road map that could be searched for disease-linked genes.
Some scientists say Iceland's genetic purity is a myth. They say the island was settled by a mixture of Scandinavians and Celts, and was as genetically varied as most European countries.
"We are not as homogenous as we were meant to be blue-eyed and blond," said Dr. Hauksson. "We were valuable because we were willing to participate."
Most Icelanders remain supportive of Decode, and the company is still a powerful force in Iceland.


Copyright © 2018 The Washington Times, LLC. Click here for reprint permission.

The Washington Times Comment Policy

The Washington Times welcomes your comments on Spot.im, our third-party provider. Please read our Comment Policy before commenting.

 

Click to Read More and View Comments

Click to Hide